In a phase 2 trial, 44% of men who received abiraterone with or without cabazitaxel prior to radical prostatectomy for high-risk prostate cancer achieved a pathologic complete response or minimal residual disease.
Computed tomography scans following neoadjuvant chemotherapy for muscle-invasive bladder cancer does not accurately predict disease burden prior to radical cystectomy.
One dose of Evusheld is administered as 2 separate, consecutive injections and may be effective for 6 months
Neoadjuvant chemotherapy response rates differed among patients with genomically unstable bladder tumors, urothelial-like bladder tumors and basal/squamous subtypes.
Progression on bacillus Calmette-Guérin (BCG) likely represents a biologically aggressive disease state as well as diagnostic delay, according to investigators.
However, many patients experience improvements in hair density with standard alopecia treatments
Findings refute the notion that variant histology MIBC will not respond to neoadjuvant chemotherapy.
Neoadjuvant chemotherapy prior to radical nephroureterectomy for upper tract urothelial carcinoma may improve pathologic outcomes regardless of age, new data suggest.
Real-world data validate recently reported findings from clinical trials.
Accurate kidney function assessment is a crucial consideration when prescribing a patient’s anticancer therapy regimen.
